ACAP Webinar: Thursday, July 24th | 2:00PM EST

As GLP-1 medications like Ozempic, Wegovy and Zepbound surge in popularity for treating diabetes and obesity, Medicaid programs across the U.S. are grappling with unprecedented financial and policy challenges.  With patients paying upwards of $11,000 annually for a year supply, and Medicaid spending on these drugs skyrocketing from $577 million in 2019 to nearly $4 billion in 2023, health plans are under immense pressure to balance access, equity and sustainability.

Join Evernorth’s panel of experts from Express Scripts Pharmacy Benefit Services for a discussion on key topics including GLP-1 utilization trends, state-by-state insights, ROI and value assessment and formulary management strategies. REGISTER NOW!